Dxd (Exatecan derivative for ADC) is a potent inhibitor of DNA topoisomerase I (IC50: 0.31 μM). It is used as a conjugated drug of HER2-targeting ADC.

#ADC-Ab0001 mouse monoclonal antibody can recognize Dxd and Dxd structurally similar molecules

1 mg/ml. Protein was determined by OD280 absorbance.

Liquid

1 mg/ml. Protein was determined by OD280 absorbance.

Dxd and Dxd structurally similar molecules

Dxd conjugated to keyhole limpethaemocyanin (KLH)

Purified by Protein A/G

Store at -20 °C. Stable for 12 months from date of receipt.

1 × PBS,pH7.4,containing 0.05% BSA, 50% glyceroland 0.03%Proclin300.

gt;90% as determined by SDS-PAGE.

ELISA

Coating by using Dxd-VLP, free Dxd added with serial dilution for competition.

IC50: 3.091 ng/ml

Coating by using an therapeutic Ab-Dxd, and added anti-Dxd antibody (ADC-Ab0001) with serial dilution.

EC50: 2.660 ng/ml

Store at -20 °C. Stable for 12 months from date of receipt.